Already at several larger institutions, CAR-T therapy is expanding rapidly due to continuing clinical trials and expected new indications in oncology. Many questions persist due to complicated administration of CAR-T therapy, especially about the role of the pathologist and the clinical laboratory. Pathologists need to be stakeholders in therapy administration, but CAR-T cell development is still a relatively unknown field. Join us for this discussion of the science behind CAR-T cell development and use in hematologic malignancies, potential adverse effects, regulatory issues, reimbursement, and future potential for CAR-T therapy in other cancers.
- Understand the science behind the development of CAR-T cells and the clinical utility of CAR-T in hematopoietic malignancies.
- List 3 possible adverse effects of CAR-T therapy administration.
- Discuss regulatory and reimbursement issues associated with CAR-T therapy.
- Recognize the future potential in CAR-T therapy in various cancers.
Handout (PDF, 1.6 MB)
Allison Cushman-Vokoun, MD, PhD, FCAP